AstraZeneca Unit Buys Biotech Co. Spirogen For $440M
MedImmune LLC, the global biologics research and development arm of British drugmaker AstraZeneca PLC, will acquire biotech company Spirogen Ltd. for up to $440 million in order to further its development...To view the full article, register now.
Already a subscriber? Click here to view full article